Retatrutide is a new treatment in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By activating these receptors, Retatrutide reduces hunger pangs, {promotesinsulin secretion, and ultimately results